Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-035377
Filing Date
2021-05-24
Accepted
2021-05-24 16:57:18
Documents
2
Period of Report
2021-05-14

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 7078
2 EX-99.1 DOCUMENT attachment1.htm EX-99.1 3950
  Complete submission text file 0001209191-21-035377.txt   13204
Mailing Address 6420 ABRAMS SAINT LAURENT A8 H4S 1Y2
Business Address 6420 ABRAMS SAINT LAURENT A8 H4S 1Y2 514-331-7440
IntelGenx Technologies Corp. (Issuer) CIK: 0001098880 (see all company filings)

EIN.: 870638336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address KRAUSENSTRASSE 9-10 BERLIN 2M 10117
Business Address KRAUSENSTRASSE 9-10 BERLIN 2M 10117 4917632963813
ATAI Life Sciences AG (Reporting) CIK: 0001776242 (see all company filings)

State of Incorp.: 2M | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 000-31187 | Film No.: 21955770

Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 (617) 699-5876
ATAI Life Sciences B.V. (Reporting) CIK: 0001840904 (see all company filings)

State of Incorp.: P7 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 000-31187 | Film No.: 21955771
SIC: 2834 Pharmaceutical Preparations